AstraZeneca suspends share repurchase programme, Core EPS target in the range of $6.00 and $6.30 unchanged

AstraZeneca suspends share repurchase programme, Core EPS target in the range of $6.00 and $6.30 unchanged

Monday, 1 October 2012

AstraZeneca today announced that it is suspending share repurchases with immediate effect. During 2012 the company has completed net share repurchases of $2.3 billion in respect of its initial target of $4.5 billion.

AstraZeneca confirms its Core EPS target range for the Full Year 2012 is maintained at $6.00 to $6.30.

Pascal Soriot, Chief Executive Officer, AstraZeneca said: "As I assume my new responsibilities at AstraZeneca, I believe this is a prudent step that maintains flexibility while the Board and I complete the company's ongoing annual strategy update."

In line with usual practice, AstraZeneca will update the market on the outlook for 2013 in conjunction with the Full Year 2012 Financial Results announcement in January.
About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit:
Media Enquiries UK

Esra Erkal-Paler +44 207 604 8030
Sarah Lindgreen +44 20 7604 8033
Media Enquiries Sweden

Ann-Leena Mikiver +46 8 553 260 20
Investor Enquiries

James Ward-Lilley +44 207 604 8122 mob: +44 7785 432613
Karl Hård +44 20 7604 8123 mob: +44 7789 654364
Nicklas Westerholm +44 20 7604 8124 mob: +44 7585 404950
Ed Seage +1 302 886 4065 mob: +1 302 373 1361

Suggested Articles

AbbVie and Allergan were already jumping through hoops for their merger before a new tax added hundreds of millions to the cost.

Avastin and Herceptin saw U.S. slowdown that's “not very pronounced” after bioisim launched, but Roche execs still warn of "a significant impact.…

Novo Nordisk, which recently completed a wastewater treatment plant for its massive U.S. API site, has made a gift of the $40 million facility.